Augmont Enterprises discloses insider trade by director's spouse
- Spouse of Augmont Director purchased 2,115 equity shares
- Aggregate traded value reached ₹20,87,434
- Transactions occurred between August 31 and September 30, 2026
- Disclosure filed under SEBI PIT Regulations, 2015

*this image is generated using AI for illustrative purposes only.
Augmont Enterprises Limited disclosed that Mrs. Priya Amit Solanki, spouse of Non-Executive Director Amitkumar Amritlal Solanki, purchased 2,115 equity shares during the quarter ended September 30, 2026.
The aggregate traded value of these transactions stood at ₹20,87,434, exceeding the ₹10,00,000 threshold prescribed under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosure was filed on October 1, 2026, with both BSE and NSE.
Transaction details
The purchases were executed on the open market across three dates in August and September 2026. The average price per share was ₹986.97.
| Date | Nature | No. of Shares | Price per Share (₹) | Traded Value (₹) |
|---|---|---|---|---|
| August 31, 2026 | Purchase | 1,008 | 956.82 | 9,64,476 |
| September 24, 2026 | Purchase | 270 | 876.37 | 2,36,621 |
| September 30, 2026 | Purchase | 837 | 1,058.94 | 8,86,337 |
| Total | - | 2,115 | 986.97 | 20,87,434 |
Note: Prices are inclusive of all charges.
Regulatory compliance
The disclosure was made by Mr. Solanki under Regulation 7(2) read with Regulation 6(2) of the SEBI PIT Regulations. The transactions were categorized as immediate relative trades. The company confirmed that the information is true and correct to the best of knowledge and requested the stock exchanges to take the disclosure on record.
Historical Stock Returns for Augmont Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +10.00% | +34.85% | +51.68% | +51.68% | +51.68% | +51.68% |
How might this insider buying signal influence institutional investor sentiment toward Augmont Enterprises in the upcoming quarter?
Will the significant price volatility observed between August and September 2026 impact Augmont's ability to secure new partnerships or funding?
Are there any pending corporate actions or strategic announcements by Augmont that could explain the timing of these open market purchases?



























